Ulinastatin ameliorates liver dysfunction during perioperative period of hepatectomy in liver cancer patients

Objective To investigate the protective effect of Ulinastatin on liver function after precise hepatectomy. Methods Fifty-six patients of hepatocellular carcinoma undergoing hepatectomy were divided into Ulinastatin group (U group, 28 cases) and control group (group C, 28 cases). Results There were no significant differences in liver function and inflammatory factors between the two groups on the 1st day before the surgry (P> 0.05). Serum ALT levels of (231±29; 140±21; 56±13; 42±6)U/L, were lower than group C (267±29; 158±23; 69±18; 53±8) U/L, all P<0.05; serum AST levels were (175±23; 94±25; 47±16; 36±8) U/L, lower than group C (191±17; 139±16; 64±15; 46±11) U/L, all P<0.05; Serum TBIL levels were (30±6; 39±9; 31±9; 21±6) μmol/L, lower than group C (34±6; 46±7; 35±8; 26±7) μmol/L, all P<0.05; Serum hs-CRP levels were (52±22; 112±23; 71±16; 42±13) mg/L, lower than group C (69±23; 129±25; 72±15; 49±15) mg/L, all P<0.05; serum IL-1β levels were (7.8±0.9; 11.1±1.5; 8.9±1.6; 5.6±0.9) pg/ml, lower than group C (9.2±1.3; 13.0±2.1; 11.1±1.4; 7.3±0.8) pg/ml, all P<0.05; Serum IL-6 levels were (187±30; 76±25; 46±15; 26±8) pg/ml; lower than group C(260±36; 92±16; 53±11; 30±8) pg/ml, all P<0.05 ; Serum TNF-α levels were (17±4; 12.0±2.4; 8.6±2.4; 6.7±2.0) pg/ml, lower than group C (25±4; 18.7±3.3; 15.0±3.1; 9.6±1.7) pg/ml, all P<0.05. Conclusion Ulinastatin protects liver function in perioperative patients undergoing precise hepatectomy. Key words: Carcinoma, hepatocellular; Hepatectomy; Perioperative period